TECHWIRE 30
(CIX: WRAL30)  996.45  down arrow-8.5  (-0.85 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Apple)  524.75  down arrow-6.95  (-1.31 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: QUINTILES)  49.47  down arrow-0.48  (-0.96 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: BASF SE)  112.59  down arrow-0.25  (-0.22 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: BioCryst)  8.55  down arrow-0.65  (-7.07 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: BioDelivery)  8.66  up arrow+0.19  (2.24 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: CEMP)  9.92  down arrow-0.49  (-4.71 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Cisco Systems)  23.50  down arrow-0.02  (-0.09 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  51.04  down arrow-7.01  (-12.08 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: DARA)  1.88  up arrow+0.05  (2.73 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: EMC CORPORATION)  25.91  down arrow-0.85  (-3.18 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Extreme Networks)  5.70  down arrow-0.09  (-1.55 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Facebook)  61.36  down arrow-1.67  (-2.65 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: GLAXOSMITHKLINE)  55.14  down arrow-0.16  (-0.29 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: GOOG)  526.94  down arrow-7.87  (-1.47 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: IBM)  191.73  down arrow-0.42  (-0.22 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NY: LH)  99.85  down arrow-0.53  (-0.53 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: Lenovo Group)  22.76  down arrow-0.43  (-1.85 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: MRK)  57.50  down arrow-0.27  (-0.47 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Microsoft Corp)  39.69  down arrow-0.3  (-0.75 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: NetApp)  35.87  down arrow-0.18  (-0.49 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: NOVARTIS AG)  86.17  down arrow-0.39  (-0.45 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: Novozymes A/S)  46.99  up arrow+0.98  (2.13 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: PFIZER)  30.92  down arrow-0.08  (-0.26 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Pozen)  9.22  down arrow-0.03  (-0.32 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: RED HAT)  50.05  down arrow-0.85  (-1.67 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: BBRY)  7.36  up arrow+0.07  (0.96 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Salix)  109.95  up arrow+0.88  (0.81 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: SQI)  26.18  down arrow-0.8  (-2.97 %)  Updated: 08:10 PM EDT, Apr 23 2014

Posts tagged “Biotech & Life Science”

Updated 1:18 p.m. yesterday

Novozymes to build $36M facility, create 100 jobs in Cary

Biofuels The company will build a new bioagriculture research and development facility in Cary. The company said it will invest $36 million over the next three years and create 100 new jobs at the facility. Salaries will start at $70,000.

12:28 p.m. yesterday

Government contracts likely mean immunity for big Novartis vaccine plant

Plans for pharmaceutical giants Novartis, GlaxoSmithKline and Eli Lilly to swap business lines may have shaken up the stock market Tuesday, but work at a Novartis flu vaccine plant in Holly Springs hummed along, and local officials said they expect it to remain that way.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated 11:22 a.m. Tuesday

Glaxo CEO: Major deals to 'improve long-term earnings'

GSK's top executive Andrew Witty says the multiple deals announced early Tuesday with Novartis promise to deliver "broadly sustainable sourced sales growth and improve long-term earnings."

Andrew Witty   Andrew Witty

Updated 11:21 a.m. Tuesday

Novartis swaps businesses with GSK, plans to sell Holly Springs plant

Novartis Two drug giants with major operations in the Triangle, Novartis and GlaxoSmithKline, are swapping businesses in two major deals. Meanwhile, Novartis plans to sell its huge Holly Springs plant in a separate deal and also strikes an agreement to sell its animal health business to Eli Lilly. No layoffs are planned, Novartis says.

Updated 11:15 a.m. Tuesday

Premium Lock Novartis-GSK deals slide show: How they change Novartis

Drug giants Novartis and GlaxoSmithKline each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the Novartis presentation.

Novartis gains GSK's oncology portfolio Novartis gains GSK's oncology portfolio

Updated 11:13 a.m. Tuesday

Premium Lock GSK-Novartis deals slide show: How they change GSK

Drug giants GlaxoSmithKline and Novartis each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the GSK presentation.

GSK's proposed new vaccine portfolio GSK's proposed new vaccine portfolio

Updated 7:55 a.m. Tuesday

Premium Lock RTP's robotic David (TransEnterix) takes on a giant (Intuitive Surgical)

TransEnterix, which is developing an innovative robotic surgery platform, completed its move to the NYSE MKT, launched its first "advanced energy flexible instrument," and is ready to take on industry leaders. But CEO Todd Pope says one of his biggest challenges early-on was convincing investors he could build the firm in the Research Triangle.

TransEnterix CEO Todd Pope TransEnterix CEO Todd Pope

6:54 a.m. Monday

Premium Lock Several Triangle firms among 45 'pitchers' at Southeast Venture Conference

The Startup Blog: The Research Triangle will be well represented at the upcoming Southeast Venture Conference in Atlanta with numerous firms already selected to be among the "pitchers" at the two-day event.

SEVC 2014 SEVC 2014

6:22 a.m. Monday

Premium Lock WSJ: Scynexis is expected to go public today, raise around $50M

The Durham drug-development company was expected to go public earlier this month, but a flagging market apparently set the Scynexis plans back. Now, The Wall Street Journal reports that today is the IPO day.

Scynexis Scynexis

5:20 a.m. Monday

Week in review: The 46 latest headlines from WRALTechWire

Week in review A look back at technology, life science and other related news as reported in WRALTechWire last week.

5:15 a.m. Monday

We want you: Send your company updates to WRALTechWire

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

April 18

W-S based Ocular says eye-eye to SightLife for corneal transplant deal

Neither organization disclosed terms of the arrangement. But they said in a joint news release that the deal makes the combined organization "the largest provider of corneal tissue for transplant in the world."

Jerry Baker Jerry Baker

April 18

Vivek Wadhwa: Why I'm excited about the promising future of medicine

Healthcare Opinion: Health care is a misnomer for our medical system. It should be called sick care. Doctors, hospitals and pharmaceutical companies only make money when we are in bad health. If we could instead prevent illness and disease, it would turn the entire medical system on its head and increase the quality of our lives. The good news is that technology is on its way to letting us do this.

April 17

GSK acknowledges more employee bribery allegations

GSK The drug giant issues a statement reiterating it has "zero tolerance for unethical or illegal behavior" and says 48 employees were fired in 2013. The statement comes after reports that bribery probes are underway in two more countries.

April 16

FDA approves once-a-week GSK injectable diabetes drug

Diabetes GlaxoSmithKline has won FDA approval for its new diabetes drug which is injectable and will be used once a week. It will compete with Novo Nordisk's Victoza, which is injected daily.

April 16

Premium Lock Med device firm TransEnterix expects to net $46M from stock offering

RTP-based medical device firm TransEnterix pulled off its $50 million stock offering and moved its shares to a different exchange on Tuesday. The company expects to net $46 million from the transaction.

TransEnterix TransEnterix

April 16

Biotech patent holders: I hate to say I told you so, but ...

Ward and Smith, P.A. TechLaw: On March 4, 2014, the U.S. Patent and Trademark Office issued new guidelines to its Patent Examiners to assist them in determining which patent claims are not eligible for patenting. The guidelines create hurdles that patent applicants must overcome in their quest for patentable claims.

April 15

Bees get a sweet boost in Bayer CropScience 'Care Center'

Bayer CropScience on Tuesday unveiled the 6,000-square-foot building to promote honey bee health and well-being through public education exhibits for visitors, a conference room and a research lab. The vision is to have students mingle with company scientists and other bee experts to study ways to reverse the decline in the important pollinators' populations.

The new Bee Care Center The new Bee Care Center

April 14

Sebelius: Healthcare.gov launch 'terribly flawed'

Obama Health Secretary Resignation The Obama administration's timeline for having ready the new health care law's online sign-up system "was just flat out wrong," outgoing Health and Human Services Secretary Kathleen Sebelius said in an interview that aired Sunday.

April 14

Week in review: The 21 latest headlines from WRALTechWire

Week in review A look back at technology, life science and other related news as reported in WRAL Tech Wire last week.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll